Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pro Medicus Limited ( (AU:PME) ) just unveiled an announcement.
Pro Medicus Limited reported a successful year both operationally and financially, attributing its achievements to its robust business model and the dedication of its staff. The company secured several new contracts, including its largest to date with Trinity Health, and continues to expand its product offerings through strategic acquisitions and licensing, strengthening its market position in North America and Germany.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, offering a suite of innovative products and services aimed at maintaining market leadership. The company focuses on providing high-quality technology solutions to healthcare providers, supported by a skilled management team and dedicated staff.
YTD Price Performance: 0.67%
Average Trading Volume: 170,664
Technical Sentiment Signal: Buy
Current Market Cap: A$26.27B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.